An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2018
At a glance
- Drugs CCX 140 (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Registrational; Therapeutic Use
- Sponsors ChemoCentryx
- 09 Oct 2018 Status changed from planning to recruiting.
- 20 Jan 2017 New trial record
- 09 Jan 2017 According to a ChemoCentryx media release, the company expects to initiate this study in 2017.